P l O I t P t tiPolyOne Investor Presentation KeyBanc Capital Markets Basic Materials & Packaging Conference September 2016p PolyOne Corporation Page 1 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Adjusted EPS is calculated as follows: Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y 2014Y 2015Y Net income (loss) attributable to PolyOne common shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 Joint venture equity earnings, after tax (68.5) (26.1) (20.8) (19.0) (14.7) (3.7) — — — — Special items, after tax(1) (51.2) 10.7 457.2 (75.9) (72.5) (72.8) 36.2 32.6 90.5 28.9 Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5 93.5 88.7 Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 Adjusted EPS Q1 2009* Q2 2009* Q3 2009* Q4 2009* Q1 2010 Q2 2010 Q3 2010 Q4 2010 Net income attributable to PolyOne common shareholders $ 3.3 $ 1.3 $ 51.3 $ 50.8 $ 20.1 $ 44.7 $ 0.1 $ 87.6 Joint venture equity earnings, after tax (8.2) (5.8) (3.0) (2.0) (0.5) (4.5) (6.2) (3.5) Special items, after tax(1) (10.2) 9.2 (36.9) (38.0) (3.8) (22.1) 25.4 (72.0) Adjusted net (loss) income $ (15.1) $ 4.7 $ 11.4 $ 10.8 $ 15.8 $ 18.1 $ 19.3 $ 12.1 Diluted shares 92.2 93.5 93.9 94.4 95.3 96.3 96.3 97.4 Adjusted EPS $ (0.16) $ 0.05 $ 0.12 $ 0.11 $ 0.17 $ 0.19 $ 0.20 $ 0.12 Adjusted EPS Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Net income attributable to PolyOne common shareholders $ 106.0 $ 23.1 $ 16.0 $ 8.3 $ 15.3 $ 18.4 $ 19.4 $ 0.2 Joint venture equity earnings, after tax (3.7) - - - - - - - Special items, after tax(1) (81.3) 1.3 2.8 4.4 6.2 8.9 5.4 15.7 Adjusted net income $ 21.0 $ 24.4 $ 18.8 $ 12.7 $ 21.5 $ 27.3 $ 24.8 $ 15.9 Diluted shares 96.4 95.5 94.0 91.9 90.7 90.7 90.2 90.5 Adjusted EPS $ 0.22 $ 0.26 $ 0.20 $ 0.14 $ 0.24 $ 0.30 $ 0.28 $ 0.18 2 Adjusted EPS Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Net income (loss) attributable to PolyOne common shareholders $ 11.2 $ 38.6 $ 23.2 $ 21.0 $ 29.4 $ 30.9 $ 32.3 $ (14.6) Special items, after tax(1) 17.7 (2.0) 12.3 4.6 12.5 17.4 13.1 47.5 Adjusted net income $ 28.9 $ 36.6 $ 35.5 $ 25.6 $ 41.9 $ 48.3 $ 45.4 $ 32.9 Diluted shares 92.8 99.1 98.1 97.2 95.7 94.3 93.1 91.3 Adjusted EPS $ 0.31 $ 0.37 $ 0.36 $ 0.26 $ 0.44 $ 0.51 $ 0.49 $ 0.36 Adjusted EPS Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Net income attributable to PolyOne common shareholders $ 30.2 $ 66.8 $ 44.5 $ 3.1 $ 39.1 $ 50.0 Special items, after tax(1) 11.4 (15.9) 3.0 30.4 9.1 3.2 Adjusted net income $ 41.6 $ 50.9 $ 47.5 $ 33.5 $ 48.2 $ 53.2 Diluted shares 90.1 89.8 88.4 86.6 85.5 84.7 Adjusted EPS $ 0.46 $ 0.57 $ 0.54 $ 0.39 $ 0.56 $ 0.63 Adjusted operating margin is calculated as follows: Adjusted operating margin Q1 2009* Q2 2009* Q3 2009* Q4 2009* YTD 2009* Q1 2010 Q2 2010 Q3 2010 Q4 2010 YTD 2010 Operating Income $ 9.9 $ 17.1 $ 57.9 $ 52.2 $ 137.1 $ 32.3 $ 58.6 $ 42.0 $ 26.3 $ 159.2 Special items (1) (1.3) 4.6 (27.5) (24.5) (48.7) - (14.5) 5.5 4.2 (4.8) Joint venture equity earnings (12.8) (9.0) (4.8) (3.1) (29.7) (0.8) (7.1) (9.7) (5.5) (23.1) Adjusted operating (loss) income $ (4.2) $ 12.7 $ 25.6 $ 24.6 $ 58.7 $ 31.5 $ 37.0 $ 37.8 $ 25.0 $ 131.3 Sales $ 463.4 $ 496.5 $ 548.3 $ 552.5 $ 2,060.7 $ 604.0 $ 666.2 $ 650.7 $ 585.3 $ 2,506.2 Operating Margin (0.9)% 2.6% 4.7% 4.5% 2.8% 5.2% 5.6% 5.8% 4.3% 5.2% Adjusted operating margin Q1 2011 Q2 2011 Q3 2011 Q4 2011 YTD 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 YTD 2012 Operating income (loss) $ 173.4 $ 42.4 $ 33.4 $ (46.2) $ 203.0 $ 37.4 $ 43.3 $ 43.5 $ 13.3 $ 137.5 Special items (1) (127.2) 2.7 4.9 72.9 (46.7) 8.5 11.8 8.3 25.3 53.9 Joint venture equity earnings (5.7) - - - (5.7) - - - - - Adjusted operating income $ 40.5 $ 45.1 $ 38.3 $ 26.7 $ 150.6 $ 45.9 $ 55.1 $ 51.8 $ 38.6 $ 191.4 Sales $ 682.8 $ 723.4 $ 694.0 $ 609.2 $ 2,709.4 $ 745.5 $ 756.6 $ 707.7 $ 651.0 $ 2,860.8 Operating Margin 5.9% 6.2% 5.5% 4.4% 5.6% 6.2% 7.3% 7.3% 5.9% 6.7% 3 Adjusted operating margin Q1 2013 Q2 2013 Q3 2013 Q4 2013 YTD 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 YTD 2014 Operating income (loss) $ 40.5 $ 80.7 $ 61.6 $ 48.7 $ 231.5 $ 56.4 $ 49.4 $ 63.6 $ (14.3) $ 155.1 Special items (1) 16.6 (5.2) 10.8 7.8 30.0 22.9 39.8 22.0 80.2 164.9 Adjusted operating income $ 57.1 $ 75.5 $ 72.4 $ 56.5 $ 261.5 $ 79.3 $ 89.2 $ 85.6 $ 65.9 $ 320.0 Sales $ 801.1 $ 1,037.6 $ 1,008.9 $ 923.6 $ 3,771.2 $ 1,002.3 $ 1,005.5 $ 958.4 $ 869.3 $ 3,835.5 Operating Margin 7.1% 7.3% 7.2% 6.1% 6.9% 7.9% 8.9% 8.9% 7.6% 8.3% Adjusted operating margin Q1 2015 Q2 2015 Q3 2015 Q4 2015 YTD 2015 Q1 2016 Q2 2016 Operating income $ 70.1 $ 80.3 $ 69.2 $ 31.3 $ 250.9 $ 71.3 $ 81.5 Special items (1) 9.3 11.9 18.7 31.4 71.3 13.8 10.4 Adjusted operating income $ 79.4 $ 92.2 $ 87.9 $ 62.7 $ 322.2 $ 85.1 $ 91.9 Sales $ 873.1 $ 887.1 $ 841.6 $ 775.8 $ 3,377.6 $ 847.0 $ 861.5 Operating Margin 9.1% 10.4% 10.4% 8.1% 9.5% 10.0% 10.7% Adjusted gross margin is calculated as follows: (In millions) Twelve Months Ended December 31, 2015 Gross margin - GAAP $ 681.5 Special items in gross margin(1) 39.7 Gross margin before special items $ 721.2 Specialty platform percentage of operating income is calculated as follows: Platform operating income mix percentage 2006Y* Q2 2016 Color, Additives and Inks $ 8.9 $ 38.2 Specialty Engineered Materials 3.9 21.4 Designed Structures and Solutions — 1.0 Specialty Platform $ 12.8 $ 60.6 Performance Products and Solutions 64.2 21.3 Distribution 19.2 17.8 Joint ventures 102.9 — Corporate and eliminations 34.5 (18.2) Operating income GAAP $ 233.6 $ 81.5 Less: Corporate and eliminations (34.5) 18.2 Operating income excluding Corporate $ 199.1 $ 99.7 Specialty platform percentage of operating income excluding corporate 6% 61% 4 Adjusted EBITDA and net debt to adjusted EBITDA is calculated as follows: (In millions) Six Months Ended June 30, 2015 Twelve Months Ended December 31, 2015 Six Months Ended June 30, 2016 Trailing Twelve Months Ended June 30, 2016 Income from continuing operations, before income taxes $ 116.7 $ 167.7 $ 123.6 $ 174.6 Interest expense, net 32.3 64.1 29.2 61.0 Depreciation and amortization 50.1 104.3 52.4 106.6 Special items, impact on income (loss) from continuing operations before income taxes(1) 21.2 87.6 24.5 90.9 Accelerated depreciation included in special items (0.3) (6.2) (3.2) (9.1) Adjusted EBITDA(2) $ 220.0 $ 417.5 $ 226.5 $ 424.0 Short-term and current portion of long-term debt $ 18.4 Long-term debt 1,126.2 Total Debt 1,144.6 Less: Cash and cash equivalents (161.4) Net Debt $ 983.2 Net Debt / TTM Adjusted EBITDA 2.3 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principal, discontinued operations or the related resegmentation 1) Special items are a non-GAAP financial measure and are used to determine adjusted earnings.

Versaflex™ HC Thermoplastic Elastomers Disinfectant Resistant Trilliant™ and Versaflex™ HC Materials Healthcare TPEs: Versaflex™ HC

Versaflex™ HC and Versaflex HC BIO Thermoplastic Elastomers (TPEs): These specialty TPE formulations offer versatile and customizable performance for medical and biopharmaceutical tubing, device overmolds, and injection molded applications. Available in a variety of durometers and performance characteristics, the product family includes grades formulated without animal derivatives and a bio-based Versaflex HC BIO BT218 formulation developed specifically to handle the complexities of biopharmaceutical tubing (excellent weldability, kink resistance, and low levels of leachables and extractables) with a lower carbon footprint than traditional Versaflex HC TPE or silicone alternatives.

Get Help Now +1-866-737-2066 Versaflex™ GP 2810-40 AM Versaflex™ CE 3120-65 AM

Versaflex™ CE 3320-70 is the first of its kind and only blue jean stain resistant thermoplastic elastomer for white and light-colored phone cases. Reduce overall costs – Versaflex CE 3320-70 has lower manufacturing and total part costs compared to silicone. VERSAFLEX CE 3320-70 Color Clear Hardness 70 Tensile Strength (PSI) 1788 Elongation % 373 www.avient.com Copyright © 2020, Avient Corporation.

GILMOUR® A Q U A A R M O R T M L I G H T W E I G H T H O S E • Lightweight • Improved kink resistance and flexibility • Soft yet durable solution for consumer appeal • Shelf differentiation • Drinking water safe • Met all requirements with a custom TPE solution, enabling Gilmour to produce a more compact hose about 50% lighter than standard PVC hoses • Incorporated custom colorants for brand consistency, and specialty additives for enhanced UV and abrasion resistance • Delivered a single-material solution for easier manufacturing, and supplied materials locally to align with customer’s “Made in the USA” brand • Provided regulatory and technical support to product development Customized Versaflex™ TPE KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/thermoplastic-elastomers/versaflex-thermoplastic-elastomers

MEDICAL TUBING EXTRUDER B I O P H A R M A C E U T I C A L T U B I N G • Low leachables & extractables • Great tensile performance and kink resistance • Good thermal weldability • Excellent clarity and medical blue tint • ISO 10993-4 & 5, USP Class VI & Animal Derivative Free (ADF) • Supplied drop-in material replacement to overcome supply constraints of incumbent TPE • Offered a lower extractable profile than comparable materials in the market • Enabled easy material transition without changes in tooling or thermal welding machine settings • Formulated solution with proprietary additives to provide clarity and prevent yellowing after sterilization Versaflex™ HC BT218 Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/thermoplastic-elastomers/versaflex-hc-thermoplastic-elastomers

O RT H O P E D I C PA RT S M A N U FAC T U R E R O R T H O P E D I C S O L E I N S E R T • A super soft TPE ( AVIENT SOLUTION HAPTICS + BIOCOMPATIBILITY LEARN MORE © 2024 Avient Corporation, All Rights Reserved https://www.avient.com/products/thermoplastic-elastomers/versaflex-thermoplastic-elastomers

Pro Forma Financial Information The Company acquired Avient Protective Materials (“Dyneema”) on September 1, 2022 (the “Acquisition Date”) and sold the Distribution segment on November 1, 2022. GUIDANCE DEBT / LEVERAGE R EDUCTION • Completed sale of Distribution and paid down $750M of debt in November • Strong free cash flow in fourth quarter reduced leverage and enabled paydown of additional $200M of debt • Fixed/Floating Debt Ratio 63/37 • Proven track record of deleveraging following acquisitions through consistent free cash flow generation $725 $725 $725 $575 $500 $400 $600 $525 $425 $650 $650 $650 $600 $2.40B $2.20B 2030 Notes 2029 Term Loan 2026 Term Loan 2025 Notes After Distribution Divestiture Year-End 4 Year-End Leverage 3.8x 3.1x 2.9x 2023 Notes After Avient Protective Materials Acquisition $3.15B 20 22 TRA NSF OR MATI ONAL PORTFOLI O ENHA NC EMENTS 5 EBITDA margins expanded from 12% to 16% Diversified end markets with reduced exposure to more cyclical industries Dyneema® Acquisition $1.48B acquisition strengthens composites platform Significantly improved EBITDA margins $950M divestiture results in 100% specialty sales Strong exit multiple of 10x TTM EBITDA despite market volatility Distribution Divestiture Improved Portfolio G ROW I NG C OM PO SI T ES P LAT F OR M C O NT R I BU TI O NS TO S EM S EG ME NT 6 Note: 2022 is pro forma for Avient Protective Materials 2016 Sales 2022 Sales Advanced Composites 51% $560M $1,300M Advanced Composites 9% C O M P O S I T E S P O R T F O L I O D Y N E E M A ® E X P A N D S O U R E N G I N E E R E D F I B E R S A N D T A P E S T E C H N O L O G Y LFT Tapes Laminates/Panels Shapes Pultrusion Engineered Fibers 7 ADVA NC ED C OM POSI TES PERFORMA NCE 8 (1) Pro forma for the acquisition of Avient Protective Materials Sales $51 $84 $212 $668 2016 2018 2020 2022 $4 $10 $41 $169 2016 2018 2020 2022 EBITDA (1) (1) ($ in millions) PORTFOLIO EVOLUTION AND EPS EXPANSION 9 Adj. EBITDA Margins (1) 5.4% 11.5% 16.2% 2006 2018 2022PF $142 $408 $592 2006 2018 2022PF 2006 figures exclude joint venture results 2022 pro forma for the acquisition of Avient Protective Materials Adj.

Versaflex™ CF Low Adhesive Build-up TPE for Protective Film Tack Layer Protective films guard the surface of finished goods from initial fabrication through assembly, shipment, storage, and installation. Versaflex™ CF 6668 low adhesion build-up TPE for protective film meets that need. Compared to current solvent- based coating technology, co-extrusion film using Versaflex CF has significantly reduced volatile organic compound (VOC) emissions and helps reduce energy consumption by eliminating secondary coating and drying operations.